| Autor: |
Federica Recine, Alessandro De Vita, Valentina Fausti, Federica Pieri, Alberto Bongiovanni, Eugenia Franchini, Roberto Casadei, Maria Cristina Falasconi, Devil Oboldi, Federica Matteucci, Maria Caterina Pallotti, Laura Mercatali, Nada Riva, Lorena Gurrieri, Silvia Vanni, Chiara Liverani, Giacomo Miserocchi, Chiara Spadazzi, Claudia Cocchi, Toni Ibrahim |
| Jazyk: |
angličtina |
| Rok vydání: |
2022 |
| Předmět: |
|
| Zdroj: |
Frontiers in Oncology, Vol 11 (2022) |
| Druh dokumentu: |
article |
| ISSN: |
2234-943X |
| DOI: |
10.3389/fonc.2021.740676 |
| Popis: |
BackgroundNTRK (neurotrophic tyrosine receptor kinase)-rearranged spindle cell neoplasms are a new group of tumors included in the new 5th edition of the World Health Organization (WHO) classification of soft Tissue and Bone Sarcomas. These tumors are characterized by NTRK gene fusions and show a wide spectrum of histologies and clinical behavior. Several targeted therapies have recently been approved for tumors harboring NTRK fusions, including STS.Case PresentationA 26-year-old male with advanced, pretreated NTRK rearranged spindle cell neoplasm and liver, lung and bone metastases was treated with larotrectinib on a continuous 28-day schedule, at a dose of 100 mg twice daily. An 18FDG-PET/CT scan performed after 7 days of treatment showed tumor shrinkage in both visceral and bone lesions. There was no drug-related toxicity. Subsequent evaluations confirmed continued tumor regression in disease sites. The patient is well and continues treatment.ConclusionThe clinical and radiological response of our patient with an uncommon TPM4 (exon 7)-NTRK1 (exon 12) gene fusion tumor treated with a first-generation TRK inhibitor could contribute to a better understanding of the biology of this new STS entity and help to improve patient management. |
| Databáze: |
Directory of Open Access Journals |
| Externí odkaz: |
|
